Favorable Response to Erlotinib in a Lung Adenocarcinoma With Both Epidermal Growth Factor Receptor Exon 19 Deletion and K-ras G13D Mutations-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Favorable Response to Erlotinib in a Lung Adenocarcinoma With Both Epidermal Growth Factor Receptor Exon 19 Deletion and K-ras G13D Mutations

Published:2010-03-01 Issue:7 Volume:28 Page:e111-e112
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Lee Chun-Nin¹,Chen Hsiang-Yin²,Liu H. Eugene³

Affiliation:

1. Department of Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan

2. Department of Pharmacy, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan

3. Department of Medicine, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2009.24.0747

Reference8 articles.

1. Somatic mutations affect key pathways in lung adenocarcinoma

2. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

3. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

4. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib;Translational Cancer Research;2019-08

2. Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study;BMC Pulmonary Medicine;2018-11-20

3. Molecular biomarkers for an early diagnosis, effective treatment and prognosis of colorectal cancer: Current updates;Experimental and Molecular Pathology;2017-06

4. Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma;Journal of Environmental Pathology, Toxicology and Oncology;2017

5. Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation;Lung Cancer;2016-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3